- Home
- IMTX vs TNGX Comparison
IMTX vs TNGX Comparison
Compare IMTX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | TNGX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMTX | TNGX |
|---|---|---|
| Price | $10.34 | $8.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $19.25 | $12.50 |
| AVG Volume (30 Days) | 623.6K | ★ 2.9M |
| Earning Date | 11-17-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,445,031.00 | $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | $24.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $3.30 | $1.03 |
| 52 Week High | $12.41 | $11.20 |
Technical Indicators
Market Signals| Indicator | IMTX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 43.42 |
| Support Level | $9.52 | $8.42 |
| Resistance Level | $10.24 | $10.08 |
| Average True Range (ATR) | 0.68 | 0.59 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 28.72 | 10.80 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.